Merck's Keytruda wins another first — this time for an FDA nod to treat a subset of bladder cancer patients
Keytruda, the star immuno-oncology therapy destined to become the world’s bestselling drug by 2024, has secured approval for a subset of bladder cancer patients that so far have not had access to checkpoint inhibitor treatment.
On Wednesday, its maker Merck said the blockbuster anti-PD-1 medicine had been sanctioned by the FDA for use in certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,000+ biopharma pros reading Endpoints daily — and it's free.